BIOGEN INC.BIIB

BIOGEN INC. Financial Overview 2021–2025

Updated Aug 8, 2026

Biogen’s Alzheimer's collaboration revenue surged by 365.3% in Q2 2025, signaling a high-stakes structural pivot. The company is actively executing a capital-intensive M&A strategy to replace its rapidly decaying multiple sclerosis franchise with new growth drivers in rare diseases and specialized immunology.

This transformation is born of necessity, as intense generic competition for TECFIDERA eroded the company's legacy foundation. Total revenue shrank from $10.98 billion in FY2021 to $9.89 billion in FY2025. To offset these structural losses, Biogen executed a series of major acquisitions, including the $6.6 billion buyout of Reata Pharmaceuticals and the $5.3 billion purchase of Apellis Pharmaceuticals. These capital allocation decisions are beginning to alter the product mix. While multiple sclerosis revenue dropped another 7.1% in FY2025, the rare disease segment grew by 8.4%, bolstered by $520.5 million in full-year sales from SKYCLARYS.

To protect bottom-line profitability during this revenue transition, management implemented a "Fit for Growth" program targeting $1.0 billion in operating expense savings. Despite heavy M&A and integration costs, the company held $4.2 billion in cash by the end of FY2025. At the close of FY2025, the market valued this ongoing turnaround with a market cap of $25.8 billion, as the stock traded at $175.99 per share with a price-to-earnings ratio of 20.0x.

Recent Developments (Q1 and Q2 2026)

Biogen formally integrated its acquisition of Apellis Pharmaceuticals in Q2 2026, immediately yielding $127.8 million in specialized immunology revenue. This strategic shift pushed Q2 2026 total revenue to $2.74 billion, a 3.4% year-over-year increase. The rare disease portfolio also advanced, growing by 10.8% during the quarter. However, the legacy multiple sclerosis franchise continued its steep decay, falling 13.0% in Q2 2026.

Bottom-line profitability took a massive hit from the ongoing portfolio transition. Q2 2026 net income plummeted to $97.5 million, pressured by integration costs and an estimated $164 million in in-process research and development expenses. Bulls argue that expanding rare disease sales and newly acquired immunology assets are successfully replacing eroding legacy revenues. Bears warn that escalating integration costs and plunging multiple sclerosis sales make the stock look richly valued at 23.8x earnings as of July 29, 2026.

What to watch: the projected $290 million to $320 million IPR&D charge expected in Q3 2026; early commercial trajectory for newly acquired SYFOVRE and EMPAVELI.

Rev

$9.89B

+2.2% YoY

FY2025

NI

$1.29B

-20.8% YoY

FY2025

EPS

$8.83

-21.2% YoY

FY2025

OCF

$2.20B

-23.3% YoY

FY2025

Revenue Trend
Beta

Year-over-year comparison from 10-K annual reports

View full history →

Data from SEC Company Facts

All BIIB Financial Metrics(61)

Recent SEC Filings

BIOGEN INC. 8-K Report, Financial Results (Jul 29, 2026)

Biogen Inc. (BIIB) has filed a Form 8-K on July 29, 2026, to announce its financial results for the second quarter ended June 30, 2026. The primary purpose of this filing is to furnish a press release detailing the company's operational and financial performance during the period. Investors should refer to the furnished press release (Exhibit 99.1) for specific details on revenue, earnings, and other key financial metrics, as well as any forward-looking statements or guidance provided by the company. While the 8-K itself is brief, it signifies the official release of Biogen's quarterly performance data. It's crucial for investors to access and analyze the accompanying press release for a comprehensive understanding of the company's recent financial health, strategic updates, and outlook. The information provided in the press release will be instrumental in evaluating Biogen's current standing and future prospects within the biotechnology sector.

BIOGEN INC. 8-K Report, Financial Results (Jul 1, 2026)

Biogen Inc. (BIIB) has filed a Form 8-K on July 1, 2026, to provide preliminary updates on its expected financial results for the second and third quarters of 2026. The primary driver of the disclosed impact is acquired in-process research and development (IPR&D), upfront, and milestone expenses related to collaborations and license agreements. These costs are significant and are expected to impact both GAAP and non-GAAP earnings per diluted share. For the second quarter of 2026, Biogen anticipates an IPR&D expense of approximately $164 million pre-tax, translating to an impact of roughly $0.95 per diluted share. Looking ahead to the third quarter of 2026, the company expects a broader range of IPR&D expenses, estimated between $290 million and $320 million, which could affect earnings per diluted share by approximately $1.75 to $1.95. Investors should note that these are preliminary estimates and are subject to change as financial closing procedures are completed.

BIOGEN INC. 8-K/A Report, Exhibit Filing (Jun 10, 2026)

Biogen Inc. (BIIB) has filed an amendment to its previous 8-K filing dated May 14, 2026. The company is clarifying that the previously disclosed acquisition of Apellis Pharmaceuticals, Inc. did not constitute a "significant" acquisition under Regulation S-X. Consequently, Biogen will not be filing the financial statements of Apellis or the pro forma financial information related to the merger as initially anticipated. This amendment is primarily an administrative update to correct the reporting requirements associated with the Apellis acquisition. Investors should note that this filing does not alter the fundamental terms or completion of the acquisition itself, but rather clarifies the regulatory reporting obligations post-transaction. The original disclosures regarding the consummation of the merger remain unchanged.

BIOGEN INC. 8-K Report, Shareholder Vote Results (Jun 10, 2026)

Biogen Inc. (BIIB) filed an 8-K on June 10, 2026, reporting the final voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. The meeting's primary outcomes included the election of ten directors to the Board and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Additionally, stockholders provided an advisory vote on executive compensation. Investors can view the detailed voting outcomes for each director nominee, which indicate overwhelming support for most candidates, with a few exceptions receiving notably fewer 'for' votes but still comfortably elected. The ratification of the auditor and the advisory vote on executive compensation also received significant stockholder approval, suggesting general confidence in the company's governance and financial oversight for the upcoming fiscal year.

BIOGEN INC. 8-K Report, Material Agreement (May 14, 2026)

Biogen Inc. (BIIB) has filed an 8-K on May 14, 2026, detailing the successful completion of its acquisition of Apellis Pharmaceuticals, Inc. The tender offer for Apellis shares concluded on May 13, 2026, with approximately 82.4% of shares tendered. Following the tender offer, Biogen completed the merger, making Apellis a wholly-owned subsidiary. The acquisition was financed through a combination of cash and $2 billion in term loan facilities secured on May 12, 2026. Key to the transaction are the Contingent Value Rights (CVRs) issued to Apellis shareholders, entitling them to potential future cash payments of up to $4.00 per CVR if specific net sales milestones for SYFOVRE® and related products are met between 2027 and 2031. Additionally, Biogen has entered into a new credit agreement, borrowing $2 billion to fund the acquisition and related expenses, which includes financial covenants such as a maximum consolidated leverage ratio of 3.75 to 1.0.

View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →